| 产品名称： | Simian foamyvirus type 3 |
|---|---|
| 商品货号： | TS178305 |
| Classification： | Retrovirus, Foamy |
| Agent： | Simian foamyvirus type 3 |
| Strain： | SFV-HU1 |
| Applications： | vaccine production |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | from a person enrolled in a surveillance program for workers at occupations with risk of exposure to nonhuman primate retroviruses |
| Storage Conditions： | -70°C or colder |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | antigenically related to nonhuman primate isolates of SFV serotype 3 This agent does not appear to have caused disease in the person from which it was isolated. potential vector for gene therapy |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (syncytia formation and cell lysis) CPE (syncytia & lysis) |
| Recommended Host： | CF2Th cells (ATCC CRL-1430) Host of Choice: CF2Th cells (ATCC CRL 1430) Host Range: A-72 (CRL 1542) & CF2Th (CRL 1430) A-72 cells (ATCC CRL-1542); CF2Th cells (ATCC CRL-1430) |
| Growth Conditions： | Duration: 4-5 days at 37C in CF2Th cells (ATCC CRL-1430) |
| Name of Depositor： | CDC |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Special Collection： | NCRR Contract |
| Source： | from a person enrolled in a surveillance program for workers at occupations with risk of exposure to nonhuman primate retroviruses |
| References： | Sandstrom PA, et al. Retrovirus isolated from humans. US Patent 5,882,912 dated Mar 16 1999 CDC, personal communication |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Simian foamyvirus type 3 |
|---|---|
| 商品货号： | TS178305 |
| Classification： | Retrovirus, Foamy |
| Agent： | Simian foamyvirus type 3 |
| Strain： | SFV-HU1 |
| Applications： | vaccine production |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | from a person enrolled in a surveillance program for workers at occupations with risk of exposure to nonhuman primate retroviruses |
| Storage Conditions： | -70°C or colder |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | antigenically related to nonhuman primate isolates of SFV serotype 3 This agent does not appear to have caused disease in the person from which it was isolated. potential vector for gene therapy |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (syncytia formation and cell lysis) CPE (syncytia & lysis) |
| Recommended Host： | CF2Th cells (ATCC CRL-1430) Host of Choice: CF2Th cells (ATCC CRL 1430) Host Range: A-72 (CRL 1542) & CF2Th (CRL 1430) A-72 cells (ATCC CRL-1542); CF2Th cells (ATCC CRL-1430) |
| Growth Conditions： | Duration: 4-5 days at 37C in CF2Th cells (ATCC CRL-1430) |
| Name of Depositor： | CDC |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Special Collection： | NCRR Contract |
| Source： | from a person enrolled in a surveillance program for workers at occupations with risk of exposure to nonhuman primate retroviruses |
| References： | Sandstrom PA, et al. Retrovirus isolated from humans. US Patent 5,882,912 dated Mar 16 1999 CDC, personal communication |
